Milestone reached in pre-clinical development!

Theralase Technologies Inc. announced today that it has identified its lead Photo Dynamic Compound (PDC) that it plans to enter into a Health Canada Clinical Trial Application (CTA)/Food and Drug Administration (FDA) Investigational New Drug (IND) Application for the destruction of Non Muscle Invasive Bladder Cancer (NMIBC) in 2015.

For more on the story, Click Here

 

 

Go back